Phase 3 Trial Data Shows Novartis Lutathera® Effective as First-line Treatment for GEP-NETs
Lutathera®, developed by Swiss drugmaker Novartis has demonstrated a substantial 72% reduction in the risk of disease progression or death
Read moreLutathera®, developed by Swiss drugmaker Novartis has demonstrated a substantial 72% reduction in the risk of disease progression or death
Read moreThe European Commission (EC) has granted marketing authorisation for Roche’s Tecentriq® SC (atezolizumab) making it the first European Union PD-(L)1
Read moreBristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read moreAstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreIn a significant development for the fight against advanced small cell lung cancer (SCLC), the U.S. Food and Drug Administration
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read moreVANFLYTA® (quizartinib) is now the first FLT3 inhibitor approved in the European Union (EU) specifically for the treatment of patients
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreOrano Med, a clinical-stage biotechnology company that develops the next generation of targeted therapies against cancer using the unique properties
Read more